Cas:104809-90-7 1 3-dinitrobenzene-ul-14c manufacturer & supplier

Chemical Name:1 3-dinitrobenzene-ul-14c

CAS.NO:104809-90-7

Synonyms:1 3-dinitrobenzene-ul-14c

Molecular Formula:C₆H₄N₂O₄

Molecular Weight:168.11

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1 3-dinitrobenzene-ul-14c chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1 3-dinitrobenzene-ul-14c physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1 3-dinitrobenzene-ul-14c Use and application,1 3-dinitrobenzene-ul-14c technical grade,usp/ep/jp grade.

Related News: European companies are the main suppliers of specialty APIs, but due to environmental and cost pressures, APIs have begun to shift to the Asian market. 1 3-dinitrobenzene-ul-14c manufacturer The patient, who arrived from Wuhan, is ��stable and under medical care,�� the ministry said in a statement, adding there is ��no cause for concern�� for the public. 1 3-dinitrobenzene-ul-14c supplier The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 1 3-dinitrobenzene-ul-14c vendor The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). 1 3-dinitrobenzene-ul-14c factory The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen��s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.